Hugo Petit Appointed CFO of OxThera

Stockholm (ots/PRNewswire) -

OxThera AB, a Stockholm-based privately-held rare disease company
today announced the appointment of Hugo Petit as its new Chief
Financial Officer. Mr Petit previously served as the Chief Financial
Officer of MedCap AB. While at MedCap, Hugo led the company's listing
on Nasdaq Stockholm. Prior to joining MedCap, Hugo held several roles
as Chief Financial Officer in small as well as medium sized
companies. Earlier in his career, Hugo also spent several years as
consultant at McKinsey & Company in Stockholm.

"It is my pleasure to welcome Hugo as CFO of OxThera," said
Matthew Gantz, CEO of OxThera. "His strong financial and business
background in both small and larger companies and recent experience
as CFO of a publically listed life sciences company will help
accelerate OxThera's growth as it further builds additional
capabilities to support our ambitions."

"I am excited to join OxThera at this important stage in its
development of Oxabact," said Mr Petit. "Primary Hyperoxaluria is a
devastating disease for patients and their families and I truly hope
that we can make a real difference and deliver on the promise of this
new therapy."

About OxThera

OxThera is developing a novel treatment, Oxabact, for Primary
hyperoxaluria (PH), a severe and often fatal disease in children, and
where there are currently no available therapies. The company has
initiated a pivotal Phase III study (EpHEX) in PH with Oxabact in
order to stop and/or delay disease progression.

Oxabact is an oral product, composed of highly concentrated
freeze-dried live bacteria (Oxalobacter formigenes). This commensal
bacteria promotes the enteric elimination of oxalate, thereby
reducing the oxalate burden in the kidneys.

PH is a rare autosomal recessive disorder leading to markedly
elevated levels of endogenous oxalate causing kidney deterioration
and a gradual calcification of soft tissues. If left untreated, the
disease can cause kidney failure and premature death. Currently, the
sole available cure is a combined transplantation of liver and
kidneys.

Oxabact holds orphan drug designations in the EU and the US for
the treatment of PH, and in EU for treatment of Short Bowel Syndrome
(SBS).

For more information please visit our website:
http://www.oxthera.com

ots Originaltext: OxThera AB
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information
please contact Matthew Gantz
CEO of OxThera Group
Matthew.gantz@oxthera.com
+14846803001

Original-Content von: OxThera AB, übermittelt durch news aktuell